Jaguar Health, Inc. (JAGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
JAGX POWR Grades
- JAGX scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.4% of US stocks.
- JAGX's strongest trending metric is Momentum; it's been moving down over the last 38 weeks.
- JAGX ranks lowest in Stability; there it ranks in the 2nd percentile.
JAGX Stock Summary
- With a year-over-year growth in debt of 179.08%, Jaguar Health Inc's debt growth rate surpasses 94.98% of about US stocks.
- In terms of volatility of its share price, JAGX is more volatile than 94.3% of stocks we're observing.
- Jaguar Health Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.95%, greater than the shareholder yield of only 5.26% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Jaguar Health Inc, a group of peers worth examining would be VYNE, FLDM, FLXN, SBBP, and BIGC.
- JAGX's SEC filings can be seen here. And to visit Jaguar Health Inc's official web site, go to www.jaguar.health.
JAGX Valuation Summary
- JAGX's price/earnings ratio is -3.7; this is 110.14% lower than that of the median Healthcare stock.
- Over the past 77 months, JAGX's price/sales ratio has gone NA NA.
- Over the past 77 months, JAGX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for JAGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| JAGX | 2021-08-31 | 24.0 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-30 | 24.0 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-27 | 24.4 | 5.4 | -3.7 | -4.5 |
| JAGX | 2021-08-26 | 24.2 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-25 | 24.4 | 5.4 | -3.7 | -4.5 |
| JAGX | 2021-08-24 | 24.0 | 5.3 | -3.7 | -4.4 |
JAGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- JAGX has a Quality Grade of C, ranking ahead of 31.46% of graded US stocks.
- JAGX's asset turnover comes in at 0.128 -- ranking 242nd of 677 Pharmaceutical Products stocks.
- MYGN, MDVL, and CDXC are the stocks whose asset turnover ratios are most correlated with JAGX.
The table below shows JAGX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 0.596 | -2.417 |
| 2021-03-31 | 0.211 | 0.673 | -4.961 |
| 2020-12-31 | 0.250 | 0.651 | 109.795 |
| 2020-09-30 | 0.232 | 0.611 | 7.457 |
| 2020-06-30 | 0.182 | 0.479 | 28.507 |
| 2020-03-31 | 0.143 | 0.282 | -249.492 |
JAGX Price Target
For more insight on analysts targets of JAGX, see our JAGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
JAGX Stock Price Chart Interactive Chart >
JAGX Price/Volume Stats
| Current price | $2.24 | 52-week high | $13.41 |
| Prev. close | $2.33 | 52-week low | $0.56 |
| Day low | $2.23 | Volume | 1,074,000 |
| Day high | $2.34 | Avg. volume | 5,871,538 |
| 50-day MA | $3.45 | Dividend yield | N/A |
| 200-day MA | $5.08 | Market Cap | 104.11M |
Jaguar Health, Inc. (JAGX) Company Bio
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Latest JAGX News From Around the Web
Below are the latest news stories about Jaguar Health Inc that investors may wish to consider to help them evaluate JAGX as an investment opportunity.
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in DogsJaguar planning for launch of Canalevia™ for CID in dogs this DecemberCanalevia is the first and only oral plant-based prescription drug candidate for CID in dogsSAN FRANCISCO, CA / ACCESSWIRE / September 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it was informed on September 21, 2021 by the FDA's Center for Veterinary Medicine (CVM) that the Target Animal Safety (TAS) technical section of the company's application for conditional approval of Canalevia for chemotherapy-ind |
Jaguar Health, Inc.: REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern TimeClick here to register for webcastJaguar kicks off educational awareness contest in honor of Indigenous Peoples'' Day; Click here to enterSAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar |
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern TimeClick here to register for webcastJaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enterSAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, September 20, 2021 at 8:30 a. |
Jaguar Health, Inc.: Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines AgencyThe conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals |
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines AgencyThe conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo PharmaceuticalsJaguar to host investor webcast Monday, September 20th at 8:30 a. Eastern; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / September 15, 2021 / Jaguar Health (NASDAQ:JAGX) today announced that the European Medicines Agency (EMA) has confirmed that the Orphan Drug Designation (ODD) ap |
JAGX Price Returns
| 1-mo | -38.80% |
| 3-mo | -52.74% |
| 6-mo | -62.29% |
| 1-year | 144.01% |
| 3-year | -98.76% |
| 5-year | -99.94% |
| YTD | -8.38% |
| 2020 | 1.75% |
| 2019 | -95.00% |
| 2018 | -89.10% |
| 2017 | -80.56% |
| 2016 | -68.00% |
Continue Researching JAGX
Here are a few links from around the web to help you further your research on Jaguar Health Inc's stock as an investment opportunity:Jaguar Health Inc (JAGX) Stock Price | Nasdaq
Jaguar Health Inc (JAGX) Stock Quote, History and News - Yahoo Finance
Jaguar Health Inc (JAGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...